Antimalaria; Plasmodium falciparum malaria
Artemotil targets the malaria parasite Plasmodium falciparum. The artemisinin derivatives, including Artemotil, exert their antimalarial activity through the endoperoxide bridge, which is thought to be activated by iron within the parasite. This activation generates free radicals that alkylate and damage parasite proteins, leading to the death of the parasite. Artemotil is rapidly converted to its active metabolite, dihydroartemisinin. The compound is effective against both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum.

In vitro tests were conducted to evaluate the antimalarial efficacy of Artemotil against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum parasites. Artemotil's 50% inhibitory concentration (IC50) ranges from 1.57 to 1.92 nM on average. Compared to artemisinin, artemotil is about 2.5 times as efficacious [1].

---

In vitro, Artemotil has been shown to have potent antimalarial activity against Plasmodium falciparum. Its activity is typically measured using standard in vitro antimalarial susceptibility assays, where the compound's ability to inhibit parasite growth is assessed. The IC50 is determined from dose-response curves. Artemotil is effective against both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum. However, specific in vitro data, such as IC50 values, are not detailed in standard product descriptions. Artemotil is a research compound used to study antimalarial drug mechanisms.

In addition to causing significant reductions in food consumption and body weight after day 2, the administration of 25 mg/kg of artemotil intravenously (i.v.) for seven days to male Sprague-Dawley rats demonstrated anorexigenic toxicity. The AUC on day 7 was five times higher than the AUC on day 1, and the elimination t1/2 of artemotil was also extended from 13.7 hours (day 1) to 31.2 hours (day 7) [2].

---

In vivo, Artemotil is used for the treatment of malaria, particularly severe malaria. It is administered by intramuscular injection. Artemotil is rapidly converted to its active metabolite, dihydroartemisinin, which is responsible for its antimalarial activity. The compound has been shown to be effective in clinical studies for the treatment of malaria. However, its use has been largely replaced by other artemisinin derivatives with better pharmacokinetic profiles. Artemotil is a research compound and an antimalarial drug.

The antimalarial activity of beta-artemether and beta-arteether was compared in three test systems: in vitro against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum parasites, in mice infected with P. berghei, and in Aotus monkeys infected with chloroquine-resistant P. falciparum. In vitro, the mean 50% inhibitory concentration (IC50) for beta-artemether was 1.74 nM (range 1.34-1.81 nM), and this value for beta-arteether was 1.61 nM (range 1.57-1.92 nM). They were approximately 2.5-fold more potent than artemisinin, which had a mean IC50 of 4.11 nM (range 3.36-4.60 nM)[1].

---

In vitro assays for Artemotil measure its antimalarial activity against Plasmodium falciparum. The standard assay involves culturing P. falciparum parasites in human erythrocytes and treating them with varying concentrations of Artemotil. After a period of incubation, parasite growth is assessed by measuring the incorporation of radiolabeled hypoxanthine or by microscopic examination. The IC50 is determined from dose-response curves. These assays confirm Artemotil's potent antimalarial activity.

In vitro cell-based assays for Artemotil are used to study its effects on the malaria parasite. P. falciparum-infected erythrocytes are treated with Artemotil at various concentrations, and parasite viability is assessed. The compound's effects on parasite development and replication are measured. These assays confirm the compound's antimalarial activity.

Animal/Disease Models: SD (SD (Sprague-Dawley)) male rats (220-280g) [2]
Doses: 25 mg/kg; 1 mL/kg body weight
Route of Administration: intravenous (iv) (iv)injection; daily; continued for 7 days
Experimental Results: Anorexigenic toxicity was observed, leading to the first Food consumption and body weight were Dramatically diminished after 2 days.

---

In the mouse model, the 50% curative doses (CD50) of beta-artemether and beta-arteether had a mean value of 55 mg/kg (32-78 mg/kg). The 50% effective curative doses (ED50) in the Aotus monkey were 7.1 mg/kg (95% confidence interval [CI] = 3.7-13.5) for beta-artemether and 11.8 mg/kg (95% CI = 6.5-21.3) for beta-arteether. Overall, the activities of the two drugs were comparable.[1]

---

In vivo animal experiments for Artemotil are conducted in animal models of malaria, such as mice infected with Plasmodium berghei or P. falciparum. In a typical study, Artemotil is administered to infected animals, and parasite load is measured over time. The compound's ability to reduce parasitemia and improve survival is assessed. These studies confirm the in vivo efficacy of Artemotil as an antimalarial agent.

Multiple administrations of Artemotil (ARTE) at a dose of 25 mg/kg to rats caused central nervous system toxicity and anorexia. This study investigated the toxicokinetics (TK) after multiple injections and the pharmacokinetics (PK) after a single dose of the same dose of ARTE. ARTE was dissolved in sesame oil and administered continuously for 7 days. Blood samples were collected within 192 hours after administration using a destructive sampling method and analyzed using high-performance liquid chromatography-electron capture detector (HPLC-ECD). Two other groups of rats received a single intravenous or intramuscular injection of 25 mg/kg ARTE, respectively. Drug residues at the intramuscular injection site were also measured. Anorexia toxicity of ARTE was observed during the 7-day treatment period, resulting in a significant decrease in food intake and body weight from day 2 onwards. Pharmacokinetic (TK) data from days 2 to 7 showed significant changes compared to the estimated pharmacokinetic (PK) parameters from day 1. The AUC on day 7 (4367 ng·h/ml) was 5 times that on day 1 (905 ng·h/ml). The steady-state volume of distribution (V(SS)) on day 7 (41.8 L) was 40% of the V(SS) value on day 1 (104.3 L). The clearance (CL) increased by 89% compared to day 1, from 0.98 L/h to 1.85 L/h on day 7. The elimination half-life of ARTE (t(1/2)) also increased from 13.7 hours (day 1) to 31.2 hours (day 7). These data suggest that ARTE may have altered its distribution and elimination in rats due to systemic toxicity. Injection site analysis showed that 38% and 91% of the total ARTE remained in muscle 24 hours after the first injection and 24 hours after 7 consecutive days of multiple daily administration, respectively. Muscle absorption occurred in two phases: rapid absorption and slow absorption, with half-lives of 0.97 hours and 26.3 hours, respectively. Due to the prolonged absorption phase in the muscle, the apparent elimination half-life of ARTE administered intramuscularly (13.7 hours) is much longer than that of intravenous injection (0.67 hours). Acute toxicity data of artemisinin-based drugs showed that animals receiving a single high dose of sesame oil-infused ARTE died within 5–11 days, similar to Artemotil. When animals were given dihydroartemisinin prepared with 50% DMAC/oil, or artesunate and Artemotil prepared with 0.9% saline, they died within 1 to 2 days. This suggests that the delayed toxicity and death of ARTE rats may also be due to slow drug absorption and prolonged drug exposure. Therefore, repeated intramuscular injections may lead to anorexia and drug accumulation, which may affect the toxicokinetics and efficacy of the drug. [2]

---

Artemotil has a molecular weight of 312.40 g/mol and a molecular formula of C17H28O5. It has a CAS number of 75887-54-6 and a UNII code of XGL7GFB9YI. It is a white crystalline solid with a melting point of 80-82°C and an alpha D21 of +154.5° (c = 1.0 in CHCl3). For storage, it is recommended to keep the compound at -20°C. Pharmacokinetic properties have been characterized. Artemotil is administered by intramuscular injection and is rapidly converted to its active metabolite, dihydroartemisinin.

Artemotil is generally well-tolerated, but it can cause side effects, including nausea, vomiting, dizziness, and headache. As with other artemisinin derivatives, it can cause neurotoxicity at high doses. Artemotil is contraindicated in patients with hypersensitivity to artemisinin derivatives. For research use, standard laboratory safety precautions should be followed when handling Artemotil.

[1]. Comparison of beta-artemether and beta-arteether against malaria parasites in vitro and in vivo. Am J Trop Med Hyg. 1993 Mar;48(3):377-84.

[2]. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):213-23.

Artemotil is an artemisinin derivative. Also known as β-artemisinin, Artemotil is a semi-synthetic derivative of artemisinin and a fast-acting hemolytic schizonticide specifically used to treat cases of Plasmodium falciparum malaria and cerebral malaria resistant to chloroquine.

---

Artemotil (Arteether, SM 227) is a semisynthetic derivative of artemisinin and an antimalarial agent. It is characterized by an endoperoxide bridge essential for its activity. Artemotil is effective against both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum. It is administered by intramuscular injection and is rapidly converted to its active metabolite, dihydroartemisinin. Artemotil has been used in the treatment of malaria, particularly severe malaria. Its use has been largely replaced by other artemisinin derivatives. It is a research compound and an antimalarial drug.

312.193

C, 65.36; H, 9.03; O, 25.61

75887-54-6

75887-54-6; 109716-83-8;

3000469

White to off-white solid powder

1.2±0.1 g/cm3

372.4±42.0 °C at 760 mmHg

80-820ºC

146.0±27.8 °C

0.0±0.8 mmHg at 25°C

1.516

3.6

0

5

2

22

443

8

O1[C@@]23[C@]4([H])O[C@@]([H])([C@]([H])(C([H])([H])[H])[C@]2([H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@]3([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(O1)O4)OC([H])([H])C([H])([H])[H]

NLYNIRQVMRLPIQ-XQLAAWPRSA-N

InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1

(1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane

Arteether; Arteether; Artemotil; 75887-54-6; Beta-Arteether; SM-227; Artemotilum; .beta.-arteether; Artemotil [INN]; Artemotil Dihydroartemisinin ethyl ether beta-Arteether NSC 665971 SM 227beta-Dihydroartemisinin ethyl ether

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~50 mg/mL (~160.05 mM)

Solubility in Formulation 1: ≥ 2.08 mg/mL (6.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: 2.08 mg/mL (6.66 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (6.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)